{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:06Z","timestamp":1787987886609,"version":"build-2784847793"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:bold>To analyze the factors associated with response to anti\u2013tumor necrosis factor<\/jats:bold>\n                      <jats:bold>(anti\u2010TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients with refractory noninfectious uveitis.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter observational study of 160 patients (39% men and 61% women; median age 31 years [interquartile range 21\u201342]) with uveitis that had been refractory to other therapies, who were treated with anti\u2010TNF (IFX 5 mg\/kg at weeks 0, 2, 6, and then every 5\u20136 weeks [n\u2009=\u200998] or ADA 40 mg every 2 weeks [n\u2009=\u200962]). Factors associated with complete response were assessed by multivariate analysis. Efficacy and safety of IFX versus ADA were compared using a propensity score approach with baseline characteristics taken into account. Subdistribution hazard ratios (SHRs) and 95% confidence intervals (95% CIs) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:bold>The main etiologies of uveitis included Beh\u00e7et's disease (BD) (36%), juvenile idiopathic arthritis (22%), spondyloarthropathy (10%), and sarcoidosis (6%). The overall response rate at 6 and 12 months was 87% (26% with complete response) and 93% (28% with complete response), respectively. The median time to complete response was 2 months. In multivariate analysis, BD and occurrence of &gt;5 uveitis flares before anti\u2010TNF initiation were associated with complete response to anti\u2010TNF (SHR 2.52 [95% CI<\/jats:bold>\n                      <jats:bold>\n                        1.35\u20134.71],\n                        <jats:italic>P<\/jats:italic>\n                        \u2009=\u20090.004 and SHR 1.97 [95% CI 1.02\u20133.84],\n                        <jats:italic>P<\/jats:italic>\n                        \u2009=\u20090.045, respectively). Side effects were reported in 28% of patients, including serious adverse events in\n                      <\/jats:bold>\n                      <jats:bold>\n                        13%. IFX and ADA did not differ significantly in terms of occurrence of complete response (SHR 0.65 [95% CI 0.25\u20131.71],\n                        <jats:italic>P<\/jats:italic>\n                        \u2009=\u20090.39), serious side effects (SHR 0.22 [95% CI 0.04\u20131.25],\n                        <jats:italic>P<\/jats:italic>\n                        \u2009=\u20090.089), or event\u2010free survival (SHR 0.55 [95% CI 0.28\u20131.08],\n                        <jats:italic>P<\/jats:italic>\n                        \u2009=\u20090.083).\n                      <\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti\u2010TNF treatment is highly effective in refractory inflammatory uveitis. BD is associated with increased odds of response. IFX and ADA appear to be equivalent in terms of efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.39667","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T10:32:10Z","timestamp":1458901930000},"page":"1522-1530","source":"Crossref","is-referenced-by-count":136,"title":["Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network"],"prefix":"10.1002","volume":"68","author":[{"given":"H\u00e9l\u00e8ne","family":"Vallet","sequence":"first","affiliation":[{"name":"H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, AP\u2010HP, Centre National de R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Autoimmunes Rares, and Universit\u00e9 Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Seve","sequence":"additional","affiliation":[{"name":"H\u00f4pital Croix Rousse Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Biard","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis and Le Centre de Recherche INSERM Paris Sorbonne Cit\u00e9, UMR 1153 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Baptiste Fraison","sequence":"additional","affiliation":[{"name":"H\u00f4pital Jean Verdier Bondy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bielefeld","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) de Dijon Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Perard","sequence":"additional","affiliation":[{"name":"H\u00f4pital Edouard Herriot Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bienvenu","sequence":"additional","affiliation":[{"name":"CHU de Caen Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Abad","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Rigolet","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, AP\u2010HP, Centre National de R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Autoimmunes Rares, and Universit\u00e9 Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[{"name":"CHU de Grenoble\u2013H\u00f4pital Michallon Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Sene","sequence":"additional","affiliation":[{"name":"H\u00f4pital Lariboisi\u00e8re, AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Perlat","sequence":"additional","affiliation":[{"name":"CHU de Rennes Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Marie","sequence":"additional","affiliation":[{"name":"CHU de Rouen Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Feurer","sequence":"additional","affiliation":[{"name":"H\u00f4pital Croix Rousse Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[{"name":"Eric Hachulla, MD, PhD: Centre Hospitalier R\u00e9gional Universitaire de Lille Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Antoine, AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Clavel","sequence":"additional","affiliation":[{"name":"A. Rothschild Foundation Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Riviere","sequence":"additional","affiliation":[{"name":"CHU de Montpellier Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Alban","family":"Bouche","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis and Le Centre de Recherche INSERM Paris Sorbonne Cit\u00e9, UMR 1153 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gueudry","sequence":"additional","affiliation":[{"name":"CHU de Rouen Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pugnet","sequence":"additional","affiliation":[{"name":"CHU de Toulouse\u2013H\u00f4pital Purpan, INSERM UMR 1027 Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc","family":"Le Hoang","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Resche Rigon","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis and Le Centre de Recherche INSERM Paris Sorbonne Cit\u00e9, UMR 1153 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, AP\u2010HP, Centre National de R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Autoimmunes Rares, and Universit\u00e9 Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, AP\u2010HP, Centre National de R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Autoimmunes Rares, and Universit\u00e9 Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the French Uveitis Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.014"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iio.0000155938.83083.94"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.027"},{"key":"e_1_2_7_5_1","first-page":"2462","article-title":"Quantitative assessment of the integrity of the blood\u2010retinal barrier in mice","volume":"43","author":"Derevjanik NL","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2008.11.005"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000055677"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00659-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.02.002"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.723107"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.903"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302292"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.018"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301401"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.07.019"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3824"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu266"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1444"},{"issue":"10","key":"e_1_2_7_24_1","article-title":"Effect of adalimumab on visual functioning (VFQ\u201025) in Visual\u20101 Trial patients with non\u2010anterior non\u2010infectious uveitis [abstract]","volume":"67","author":"Sheppard J","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes130"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12148"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204575"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61704-9"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.18433\/J3WP4F"},{"key":"e_1_2_7_30_1","first-page":"71","article-title":"Anti\u2010TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR)","volume":"32","author":"Westhovens I","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.01.010"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.7.559"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i19.6044"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202171"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39667","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:13:23Z","timestamp":1759925603000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/art.39667"],"URL":"https:\/\/doi.org\/10.1002\/art.39667","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726236864.793517450","asserted-by":"object"}]},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}